Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With A...(f endometriosis is pelvic pain. The pain...)

Date:2/6/2008

f endometriosis is pelvic pain. The pain often correlates to the menstrual cycle, but a woman with endometriosis may also experience pain that doesn't correlate to her cycle. For many women, the pain of endometriosis is so severe and debilitating that it impacts their daily lives in significant ways.

It is estimated that seven to 10 percent of all women are affected by endometriosis, including 70 to 87 percent of women with chronic pelvic pain and 30 to 40 percent of all infertile women. Chronic pelvic pain, dysmenorrhea (painful periods) and dyspareunia (painful intercourse) are common symptoms of women with endometriosis. There are several medical treatment options, including danazol, GnRH agonists and progestins, each of which have limitations associated with patient response, tolerability, side- effect profile and duration of treatment.

"I am pleased that Meditrina will be pursing this indication, leveraging the work done to date by AstraZeneca. Anastrozole in combination with an estrogen and progestin in the area of women's gynecologic indications represents a valid medical approach and sits well with Meditrina's strategic focus and expertise," commented Dr. John Patterson, Executive Director, Research and Development, AstraZeneca.

Terms of the agreement were not disclosed.

About Meditrina Pharmaceuticals, Inc.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs. By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina's novel therapies have the potential to significantly alter the way these women's health conditions are treated. For more information about Meditrina Pharmaceuticals, please visit

SOURCE Meditrina Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
8. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
11. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007